• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Exclusive

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

Commentary

Marijuana Could Be the Answer to the NFL’s Pain Management Woes

By
Stephen B. Corn
Stephen B. Corn
and
Bethany Cianciolo
Bethany Cianciolo
Down Arrow Button Icon
By
Stephen B. Corn
Stephen B. Corn
and
Bethany Cianciolo
Bethany Cianciolo
Down Arrow Button Icon
August 9, 2017, 4:16 PM ET
Marijuana Cultivation Center In Nevada Ramps Up Production As State Legalizes Recreation Use Of Weed
LAS VEGAS, NV - JULY 06: David Burr demonstrates removing leaves on marijuana plants to allow more light for growth at Essence Vegas' 54,000-square-foot marijuana cultivation facility on July 6, 2017 in Las Vegas, Nevada. On July 1, Nevada joined seven other states allowing recreational marijuana use and became the first of four states that voted to legalize recreational sales in November's election to allow dispensaries to sell cannabis for recreational use to anyone over 21. Since July 1, sales of cannabis products in the state have generated more than USD 1 million in tax revenue. (Photo by Ethan Miller/Getty Images)Ethan Miller—Getty Images

Last month, it was reported that the National Football League reached out to the National Football League Players Association to scientifically explore the use of medical cannabis as a pain management tool for its players. Not only should this work help the NFL players, but their participation in these studies may likely advance pain management for the millions of people suffering with chronic pain.

As a board-certified physician specializing for over 25 years in anesthesiology, perioperative medicine, and pain medicine, and serving as an associate professor of anesthesiology at Harvard Medical School, I know how difficult it can be to treat acute and chronic pain issues. All of our sanctioned treatments have side effects, with addiction and opioid-induced respiratory arrest being among the most significant, causing much morbidity and mortality.

Chronic pain can be defined as pain lasting longer than three to six months in duration and often has a poorly defined onset. This pain is associated with subjective complaints, but objective physical signs may or may not be present as the patient adapts to the pain. Chronic pain can be devastating, affecting one’s physical and mental health. Though many treatment modalities exist, including medications (non-steroidal anti-inflammatory, opioids, and anti-depressants), peripheral nerve blocks, implantable systems (spinal cord stimulators, pain pumps), physical therapy, and acupuncture, all too often, effective pain management remains elusive.

Interestingly, each and every one of us possesses an endocannabinnoid system (ECS) that binds with cannabis. The endocannabinoid system is an internal homeostatic system that plays a critical role in the nervous system and regulates multiple physiological processes, including the modulation of pain, appetite, digestion, mood, seizure threshold, coordination, and other processes. Cannabinoid receptors exist in the brain, spinal cord, and peripheral nervous system. Further, these receptors are present in areas of the brain related to pain perception and emotion.

According to the 2017 National Academies of Science, Engineering and Medicine’s report, Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, there is conclusive or substantial evidence that cannabis or cannabinoids are effective for the treatment of chronic pain. That report also found that there is evidence of a statistical association between cannabinoids and better outcomes (i.e., decreased mortality, decreased disability) after a traumatic brain injury.

The aforementioned biology, coupled with the scientific research evidence makes it most reasonable to explore cannabis as a means to tackle the NFL pain management challenges.

NFL players are a population of able-bodied individuals, comprising a homogenous population of males who may also have a lower prevalence of co-existing disease than other study participants from the general population. Thus, the NFL players may provide an excellent, and perhaps willing, study population for randomized controlled trials of medical cannabis.

 

Multiple outcomes could be realized from studies performed by the NFL, as they could potentially demonstrate the level of efficacy and safety of medical cannabis for the treatment of acute and chronic pain. Furthermore, the effects and safety profile of medical cannabis could be compared to that of opioid therapy, and opioid therapy in combination with medical cannabis. In addition, the level of impairment due to opioid therapy can be compared to that of medical cannabis therapy. Also, the long-term results of these NFL studies may clarify the addictive potential of medical cannabis compared to opioid therapy and may shed light on cannabis’s potential to prevent chronic traumatic encephalopathy (CTE).

Finally, from interacting with patients utilizing medical cannabis, it is evident that many just want to use enough cannabis to decrease their symptoms and improve their function so that they can perform in the home and workplace. Interestingly, an often-discussed benefit voiced by medical cannabis patients with chronic pain is their success in eliminating medication side effects by decreasing or discontinuing the use of multiple prescription pain medications by substituting with medical cannabis. Perhaps collaboration between the NFL and the National Football League Players Association can result in studies that address these issues as well, and lead to effective treatment regimes for players and chronic pain patients.

Stephen B. Corn, MD, is an associate professor of Harvard Medical School and founder of TheAnswerPage.com.

About the Authors
By Stephen B. Corn
See full bioRight Arrow Button Icon
By Bethany Cianciolo
See full bioRight Arrow Button Icon

Latest in Commentary

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Commentary

altman
CommentarySam Altman
Musk vs. Altman: AI safety cannot be one man’s job
By Stavros GadinisMay 18, 2026
10 hours ago
charlie
CommentarySoftware
Anaplan CEO: AI isn’t eating software. It’s sorting it
By Charlie GottdienerMay 18, 2026
20 hours ago
shyam
CommentaryHealth
World Economic Forum: women’s health gets only 20% of R&D funding. We must seize this $1 trillion opportunity
By Shyam BishenMay 18, 2026
1 day ago
murdochs
CommentaryMedia
OpenAI paid $100 million for a talk show. James Murdoch is eyeing an even bigger deal. The hot new asset class is humanity
By Lin CherryMay 17, 2026
2 days ago
dennis
CommentaryAI agents
Freshworks CEO: why agile enterprises are winning the AI race — and what they did differently
By Dennis WoodsideMay 17, 2026
2 days ago
Mary Moreland-Abbott Executive Vice President of Human Resources.
CommentaryRetirement
Gen X is the most indebted generation in America. Their employers can fix that
By Mary MorelandMay 17, 2026
2 days ago

Most Popular

The Bezos family just donated $100 million to help achieve one of Mayor Zohran Mamdani’s top campaign promises
Politics
The Bezos family just donated $100 million to help achieve one of Mayor Zohran Mamdani’s top campaign promises
By Jake AngeloMay 12, 2026
6 days ago
While Trump insisted the Iran war would end ‘soon,’ an account in his name was buying millions in oil, defense and gold
Economy
While Trump insisted the Iran war would end ‘soon,’ an account in his name was buying millions in oil, defense and gold
By Eva RoytburgMay 18, 2026
12 hours ago
Microsoft AI chief gives it 18 months—for all white-collar work to be automated by AI
AI
Microsoft AI chief gives it 18 months—for all white-collar work to be automated by AI
By Jake AngeloMay 16, 2026
3 days ago
Current price of oil as of May 18, 2026
Personal Finance
Current price of oil as of May 18, 2026
By Joseph HostetlerMay 18, 2026
18 hours ago
EXCLUSIVE: An hour in the Oval Office with the CEO-in-Chief, President Trump
Politics
EXCLUSIVE: An hour in the Oval Office with the CEO-in-Chief, President Trump
By Alyson ShontellMay 18, 2026
1 day ago
The top foreign holders of U.S. debt may soon dump Treasury bonds and bring their money back home, potentially spiking borrowing costs
Economy
The top foreign holders of U.S. debt may soon dump Treasury bonds and bring their money back home, potentially spiking borrowing costs
By Jason MaMay 17, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.